Aug 28, 2019
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
Aug 07, 2019
Blue Water Vaccines, Developing Universal Flu Vaccine, to Partner With Ology Bioservices Inc.
Jul 26, 2019
Flu Vaccines Market is Projected to Reach Approx. US$ 8 Bn by 2029 - PMR
Jul 16, 2019
BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
Jul 09, 2019
Fluzone High Dose (inactivated split virion; Sanofi Pasteur) Drug Overview & Product Profiles 2017-2026
Jul 08, 2019
First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
Jul 01, 2019
Global H1N1 Vaccines Market 2019-2024: Analysis of Key Brands - Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip, Others
Jun 18, 2019
Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan
Jun 10, 2019
BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process
Jun 05, 2019
Vaccitech Universal Flu Vaccine Passes Phase 2b Clinical Development Milestones
May 30, 2019
BiondVax Announces First Quarter 2019 Financial Results
May 13, 2019
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
Apr 30, 2019
BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
Apr 25, 2019
Medicago Awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress
Apr 22, 2019
European Investment Bank (EIB) Extends Financing Agreement to EUR24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial
Apr 15, 2019
BiondVax Universal Flu Vaccine Patent Application Accepted in Australia
Mar 28, 2019
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference
Mar 21, 2019
Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate
Feb 06, 2019
Global H1N1 Vaccines Market 2018 - Industry Analysis, Trends, Market Size and Forecasts up to 2024
Jan 23, 2019
FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age